Peritoneal carcinomatosis after risk‐reducing surgery in <i>BRCA1/2</i> mutation carriers
Marline G. Harmsen(Radboud University Nijmegen), Joanne A. de Hullu(Radboud University Nijmegen), Jurgen M.J. Piek(Radboud University Nijmegen), Marc van Beurden(Oncode Institute), Leon F.A.G. Massuger(Radboud University Nijmegen), Johan Bulten(Radboud University Nijmegen), Timothy R. Rebbeck(Dana-Farber Cancer Institute), Mark H. Greene(Cancer Institute (WIA)), Marian J.E. Mourits(Radboud University Nijmegen), Murray Joseph Casey(Creighton University), B.F.M. Slangen(Maastricht University Medical Centre)
Cited by 40
Related Papers
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k
Metabolic gene polymorphism frequencies in control populations.
|PubMed|2001|847
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661